BR112022023503A2 - Derivados de 3-((1h-pirazol-4-il)metil)-6'-(fenil)-2h-(1,2'-bipiridin)-2-ona e compostos relacionados como antagonistas de gpr139 para uso em método de tratamento de, por exemplo, depressão - Google Patents
Derivados de 3-((1h-pirazol-4-il)metil)-6'-(fenil)-2h-(1,2'-bipiridin)-2-ona e compostos relacionados como antagonistas de gpr139 para uso em método de tratamento de, por exemplo, depressãoInfo
- Publication number
- BR112022023503A2 BR112022023503A2 BR112022023503A BR112022023503A BR112022023503A2 BR 112022023503 A2 BR112022023503 A2 BR 112022023503A2 BR 112022023503 A BR112022023503 A BR 112022023503A BR 112022023503 A BR112022023503 A BR 112022023503A BR 112022023503 A2 BR112022023503 A2 BR 112022023503A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- gpr139
- bipyridin
- pyrazol
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020090111A JP2021183587A (ja) | 2020-05-22 | 2020-05-22 | 複素環化合物 |
| PCT/IB2021/000337 WO2021234451A1 (en) | 2020-05-22 | 2021-05-20 | 3-((1h-pyrazol-4-yl)methyl)-6'-(phenyl)-2h-(1,2'-bipyridin)-2-one derivatives and related compounds as gpr139 antagonists for use in a method of treatment of e.g. depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022023503A2 true BR112022023503A2 (pt) | 2023-01-17 |
Family
ID=76797026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022023503A BR112022023503A2 (pt) | 2020-05-22 | 2021-05-20 | Derivados de 3-((1h-pirazol-4-il)metil)-6'-(fenil)-2h-(1,2'-bipiridin)-2-ona e compostos relacionados como antagonistas de gpr139 para uso em método de tratamento de, por exemplo, depressão |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12590086B2 (https=) |
| EP (1) | EP4153581A1 (https=) |
| JP (3) | JP2021183587A (https=) |
| KR (1) | KR20230015946A (https=) |
| CN (1) | CN116171276A (https=) |
| AR (1) | AR122143A1 (https=) |
| AU (1) | AU2021276623A1 (https=) |
| BR (1) | BR112022023503A2 (https=) |
| CA (1) | CA3178798A1 (https=) |
| IL (1) | IL298275A (https=) |
| MX (1) | MX2022014576A (https=) |
| TW (1) | TW202208346A (https=) |
| WO (1) | WO2021234451A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021183587A (ja) * | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | 複素環化合物 |
| GB202206054D0 (en) * | 2022-04-26 | 2022-06-08 | Cerevance Ltd | Novel Compounds |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001500852A (ja) | 1996-08-27 | 2001-01-23 | プレーシス ファーマスーティカルズ インコーポレイテッド | Ｄ―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター |
| DE19736352C1 (de) | 1997-08-21 | 1998-12-10 | Atotech Deutschland Gmbh | Vorrichtung zur Kontaktierung von flachem Behandlungsgut in Durchlaufgalvanisieranlagen |
| CA2374610A1 (en) | 1999-06-28 | 2001-01-04 | Jordan J. N. Tang | Catalytically active recombinant memapsin and methods of use thereof |
| ATE448784T1 (de) | 2002-02-14 | 2009-12-15 | Pharmacia Corp | Substituierte pyridinone als modulatoren für p38 map kinase |
| US8148367B2 (en) | 2007-01-12 | 2012-04-03 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
| WO2008094556A2 (en) | 2007-01-30 | 2008-08-07 | Biogen Idec Ma Inc. | Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists |
| WO2011145735A1 (ja) | 2010-05-21 | 2011-11-24 | 武田薬品工業株式会社 | チアゾール誘導体 |
| WO2017222952A1 (en) | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
| PL3829581T3 (pl) | 2018-07-27 | 2024-07-01 | Arcus Biosciences, Inc. | Antagoniści pirydonu a2r |
| WO2020097609A1 (en) * | 2018-11-09 | 2020-05-14 | Blackthorn Therapeutics, Inc. | Gpr139 receptor modulators |
| JP2020090111A (ja) | 2018-12-03 | 2020-06-11 | パイオニア株式会社 | 発光システム |
| JP2021183586A (ja) | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | 複素環化合物 |
| JP2021183587A (ja) | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | 複素環化合物 |
-
2020
- 2020-05-22 JP JP2020090111A patent/JP2021183587A/ja active Pending
-
2021
- 2021-05-20 JP JP2022570532A patent/JP7734153B2/ja active Active
- 2021-05-20 US US17/999,514 patent/US12590086B2/en active Active
- 2021-05-20 TW TW110118337A patent/TW202208346A/zh unknown
- 2021-05-20 CA CA3178798A patent/CA3178798A1/en active Pending
- 2021-05-20 BR BR112022023503A patent/BR112022023503A2/pt unknown
- 2021-05-20 CN CN202180059093.3A patent/CN116171276A/zh active Pending
- 2021-05-20 AR ARP210101387A patent/AR122143A1/es unknown
- 2021-05-20 IL IL298275A patent/IL298275A/en unknown
- 2021-05-20 WO PCT/IB2021/000337 patent/WO2021234451A1/en not_active Ceased
- 2021-05-20 AU AU2021276623A patent/AU2021276623A1/en active Pending
- 2021-05-20 EP EP21737769.6A patent/EP4153581A1/en active Pending
- 2021-05-20 MX MX2022014576A patent/MX2022014576A/es unknown
- 2021-05-20 KR KR1020227044430A patent/KR20230015946A/ko active Pending
-
2025
- 2025-08-25 JP JP2025139595A patent/JP2025170366A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230015946A (ko) | 2023-01-31 |
| US12590086B2 (en) | 2026-03-31 |
| US20230357220A1 (en) | 2023-11-09 |
| TW202208346A (zh) | 2022-03-01 |
| AU2021276623A1 (en) | 2022-12-22 |
| AR122143A1 (es) | 2022-08-17 |
| CN116171276A (zh) | 2023-05-26 |
| WO2021234451A1 (en) | 2021-11-25 |
| JP7734153B2 (ja) | 2025-09-04 |
| IL298275A (en) | 2023-01-01 |
| MX2022014576A (es) | 2023-02-14 |
| EP4153581A1 (en) | 2023-03-29 |
| JP2023528281A (ja) | 2023-07-04 |
| CA3178798A1 (en) | 2021-11-25 |
| JP2025170366A (ja) | 2025-11-18 |
| JP2021183587A (ja) | 2021-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pandi-Perumal et al. | Drug insight: the use of melatonergic agonists for the treatment of insomnia—focus on ramelteon | |
| RU2613177C2 (ru) | Способ применения 4-((1r,3s)-6-хлор-3-фенилиндан-1-ил)-1,2,2-триметилпиперазина и его солей в лечении шизофрении | |
| MA32898B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone | |
| CY1114329T1 (el) | Νεοι προσδετες υποδοχεων αδενοσινης και χρησεις εξ' αυτων | |
| BR112022023503A2 (pt) | Derivados de 3-((1h-pirazol-4-il)metil)-6'-(fenil)-2h-(1,2'-bipiridin)-2-ona e compostos relacionados como antagonistas de gpr139 para uso em método de tratamento de, por exemplo, depressão | |
| CA2332814C (en) | Combination therapy for treatment of refractory depression | |
| TW201002701A (en) | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | |
| AR059183A1 (es) | Uso de derivados de 2- imidazol o imidazolina sustituidos para preparar medicamentos | |
| UY28940A1 (es) | Derivados de quinazolina | |
| ATE445609T1 (de) | Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen | |
| Hagiwara et al. | Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors | |
| US20250228838A1 (en) | Methods of use of cyclic amide derivatives to treat sigma receptor mediated disorders | |
| DE602005019043D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| DE602006012725D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| BRPI0413584A (pt) | composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de doenças e para tratamento de um distúrbio no sistema nervoso central | |
| BRPI0508724A (pt) | derivados do fenilaminoetanol como agonistas do receptor beta2 | |
| Olivier et al. | Anxiolytic effects of flesinoxan in the stress-induced hyperthermia paradigm in singly-housed mice are 5-HT1A receptor mediated | |
| Sakaue et al. | Involvement of benzodiazepine binding sites in an antiaggressive effect by 5-HT1A receptor activation in isolated mice | |
| CN1989103A (zh) | 作为nmda受体拮抗剂的吲哚－2－甲脒衍生物 | |
| Davies et al. | A novel series of benzimidazole NR2B-selective NMDA receptor antagonists | |
| DE602006015509D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| BRPI0508975A (pt) | formas de dosagem e composições farmacêuticas | |
| BRPI0514463A (pt) | antagonistas do receptor de 5-ht7 | |
| BRPI0816571A2 (pt) | "composto, processo para preparação do composto, composição farmacêutica, agente e método para o tratamento de uma doença ou uma desordem do sistema nervoso central relacionada à ou afetada pelo recptor 5-ht6" | |
| BRPI0414494A (pt) | compostos, composições farmacêuticas, e, uso de um composto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |